Joseph Jankovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joseph Jankovic has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Hao Deng
Health Management Center, the Third Xiangya Hospital, Central South University, Changsha, China
5 shared publications Giovanni Mostile
Department of Neurology, Parkinson Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, USA
4 shared publications- Joohi Jimenez-Shahed
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA
4 shared publications Kevin Dat Vuong
4 shared publicationsOctavian R. Adam
Division of Neurology, Naval Medical Center, Portsmouth, USA
4 shared publicationsAnthony Davidson
3 shared publications
Latest Publications
- 1 July 2017
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 40, 18-26
Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial
- 1 July 2017
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 40, 18-26
Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial
- 18 April 2016
- Published by Springer Nature in Drugs
- Vol. 76 (7) , 779-787
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia
Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. The main types of drug-induced dyskinesias include levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease and tardive syndrome (TS), typically present in patients with psychiatric or gastrointenstinal disorders treated with dopamine receptor blocking drugs, also referred to as neuroleptics. Besides preventive measures (i.e., avoiding the use of the offending drugs), general treatment strategies include slow taper of the offending agent and use of dopamine-depleting agents like tetrabenazine. Botulinum toxin may be helpful for wearing off focal dystonia and some forms of tardive dystonia. Deep brain stimulation is usually reserved for patients with disabling motor fluctuations, LID, and for severe TS that cannot be managed medically.
- 18 April 2016
- Published by Springer Nature in Drugs
- Vol. 76 (7) , 779-787
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia
Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. The main types of drug-induced dyskinesias include levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease and tardive syndrome (TS), typically present in patients with psychiatric or gastrointenstinal disorders treated with dopamine receptor blocking drugs, also referred to as neuroleptics. Besides preventive measures (i.e., avoiding the use of the offending drugs), general treatment strategies include slow taper of the offending agent and use of dopamine-depleting agents like tetrabenazine. Botulinum toxin may be helpful for wearing off focal dystonia and some forms of tardive dystonia. Deep brain stimulation is usually reserved for patients with disabling motor fluctuations, LID, and for severe TS that cannot be managed medically.
- 18 April 2016
- Published by Springer Nature in Drugs
- Vol. 76 (7) , 759-777
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. Levodopa-induced dyskinesia (LID) is one of the main types of drug-induced dyskinesia, occurring in patients with Parkinson’s disease (PD) who have been treated with levodopa for long time, but this side effect may be encountered even within a few weeks or months after initiation of levodopa therapy. Based on the temporal pattern in relationship to levodopa dosing, LIDs are divided into “peak-dose dyskinesia,” “diphasic dyskinesia,” and “wearing off” or “off-period” dyskinesia, of which peak-dose dyskinesia is the most common, followed by off-period, and then diphasic dyskinesia. Treatment strategy includes identifying the kind of dyskinesia and tailoring treatment accordingly. Peak-dose dyskinesia is treated mainly by reducing individual doses of levodopa and adding amantadine and dopamine agonists, whereas off-period dystonia often responds to baclofen and botulinum toxin injections. Diphasic dyskinesias, occurring particularly in patients with young-onset PD, are the most difficult to treat. While fractionation of levodopa dosage is the most frequently utilized strategy, many patients require deep brain stimulation to control their troublesome motor fluctuations and LIDs. A variety of emerging (experimental) drugs currently in development promise to provide better control of LIDs and other levodopa-related complications in the near future.
- 18 April 2016
- Published by Springer Nature in Drugs
- Vol. 76 (7) , 759-777
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. Levodopa-induced dyskinesia (LID) is one of the main types of drug-induced dyskinesia, occurring in patients with Parkinson’s disease (PD) who have been treated with levodopa for long time, but this side effect may be encountered even within a few weeks or months after initiation of levodopa therapy. Based on the temporal pattern in relationship to levodopa dosing, LIDs are divided into “peak-dose dyskinesia,” “diphasic dyskinesia,” and “wearing off” or “off-period” dyskinesia, of which peak-dose dyskinesia is the most common, followed by off-period, and then diphasic dyskinesia. Treatment strategy includes identifying the kind of dyskinesia and tailoring treatment accordingly. Peak-dose dyskinesia is treated mainly by reducing individual doses of levodopa and adding amantadine and dopamine agonists, whereas off-period dystonia often responds to baclofen and botulinum toxin injections. Diphasic dyskinesias, occurring particularly in patients with young-onset PD, are the most difficult to treat. While fractionation of levodopa dosage is the most frequently utilized strategy, many patients require deep brain stimulation to control their troublesome motor fluctuations and LIDs. A variety of emerging (experimental) drugs currently in development promise to provide better control of LIDs and other levodopa-related complications in the near future.
- 9 December 2014
- Published by Wiley in Movement Disorders
- Vol. 30 (2) , 171-179
Myorhythmia: Phenomenology, etiology, and treatment
Myorhythmia is defined as repetitive, rhythmic, slow (1‐4 Hz) movement affecting chiefly cranial and limb muscles. When occurring in the limbs it may be oscillatory and jerky, whereas oculo‐masticatory myorhythmia, typically associated with Whipple's disease, is a slow, repetitive, often asymmetrical, facial and ocular movement. Thus, myorhythmia overlaps phenomenologically with tremor and segmental myoclonus. Although often present at rest, it must be differentiated from parkinsonian or dystonic tremor. Recognition of this movement disorder is important because it is usually associated with lesions involving the brainstem, thalamus, or other diencephalic structures with potentially treatable etiologies. In addition to Whipple's disease, myorhythmia has been described in patients with cerebrovascular disease, listeria encephalitis, anti‐N‐methyl‐d‐aspartate receptor encephalitis, steroid‐responsive encephalopathy associated with autoimmune thyroiditis, multiple sclerosis, and other disorders. In addition to our own experience, we have systematically reviewed the medical literature, focusing on the phenomenology, pathophysiology, and etiology of this poorly recognized movement disorder. In this review, we aim to highlight the clinical features that differentiate myorhythmia from other movement disorders. Treatment should be directed against the underlying etiology. © 2014 International Parkinson and Movement Disorder Society
- 9 December 2014
- Published by Wiley in Movement Disorders
- Vol. 30 (2) , 171-179
Myorhythmia: Phenomenology, etiology, and treatment
Myorhythmia is defined as repetitive, rhythmic, slow (1‐4 Hz) movement affecting chiefly cranial and limb muscles. When occurring in the limbs it may be oscillatory and jerky, whereas oculo‐masticatory myorhythmia, typically associated with Whipple's disease, is a slow, repetitive, often asymmetrical, facial and ocular movement. Thus, myorhythmia overlaps phenomenologically with tremor and segmental myoclonus. Although often present at rest, it must be differentiated from parkinsonian or dystonic tremor. Recognition of this movement disorder is important because it is usually associated with lesions involving the brainstem, thalamus, or other diencephalic structures with potentially treatable etiologies. In addition to Whipple's disease, myorhythmia has been described in patients with cerebrovascular disease, listeria encephalitis, anti‐N‐methyl‐d‐aspartate receptor encephalitis, steroid‐responsive encephalopathy associated with autoimmune thyroiditis, multiple sclerosis, and other disorders. In addition to our own experience, we have systematically reviewed the medical literature, focusing on the phenomenology, pathophysiology, and etiology of this poorly recognized movement disorder. In this review, we aim to highlight the clinical features that differentiate myorhythmia from other movement disorders. Treatment should be directed against the underlying etiology. © 2014 International Parkinson and Movement Disorder Society
- 1 June 2014
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20 (6) , 640-643
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial
- 1 June 2014
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20 (6) , 640-643
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial
- 10 May 2013
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 17 (1) , 104-106
Deep Brain Stimulation of the Subthalamic Nucleus for Peripherally Induced Parkinsonism
- 10 May 2013
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 17 (1) , 104-106
Deep Brain Stimulation of the Subthalamic Nucleus for Peripherally Induced Parkinsonism
- 11 February 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (4) , 543-547
The spectrum of movement disorders in children with anti‐NMDA receptor encephalitis
Background: Movement disorders are frequent but difficult to characterize in patients with anti‐N‐methyl‐d‐aspartate receptor (NMDAR) encephalitis.Methods: The phenomenology of movement disorders was characterized after a detailed examination of children with anti‐NMDAR‐encephalitis.Results: We studied 9 children (5 females), ages 3–14 years, with confirmed anti‐NMDAR‐encephalitis. All patients presented with at least 1 movement disorder, including chorea (n=4), stereotypic movements (n=4), ataxia (n=3), limb dystonia (n=2), limb myorhythmia (n=2), oromandibular dystonia (n=2), facial myorhythmia, blepharospasm, opisthotonus, athetosis, and tremor (n=1, each). More than a single movement disorder was observed in 6 of these patients. Resolution of the abnormal movements was observed in all patients with immunotherapy; 1 patient improved with tetrabenazine.Conclusions: A wide variety of movement disorders, often in combination, can be observed in children with anti‐NMDAR encephalitis. Patients commonly present with more than a single movement disorder. © 2013 Movement Disorder Society
- 11 February 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (4) , 543-547
The spectrum of movement disorders in children with anti‐NMDA receptor encephalitis
Background: Movement disorders are frequent but difficult to characterize in patients with anti‐N‐methyl‐d‐aspartate receptor (NMDAR) encephalitis.Methods: The phenomenology of movement disorders was characterized after a detailed examination of children with anti‐NMDAR‐encephalitis.Results: We studied 9 children (5 females), ages 3–14 years, with confirmed anti‐NMDAR‐encephalitis. All patients presented with at least 1 movement disorder, including chorea (n=4), stereotypic movements (n=4), ataxia (n=3), limb dystonia (n=2), limb myorhythmia (n=2), oromandibular dystonia (n=2), facial myorhythmia, blepharospasm, opisthotonus, athetosis, and tremor (n=1, each). More than a single movement disorder was observed in 6 of these patients. Resolution of the abnormal movements was observed in all patients with immunotherapy; 1 patient improved with tetrabenazine.Conclusions: A wide variety of movement disorders, often in combination, can be observed in children with anti‐NMDAR encephalitis. Patients commonly present with more than a single movement disorder. © 2013 Movement Disorder Society
- 3 December 2012
- Published by Wiley in Movement Disorders
- Vol. 27 (14) , 1816-1819
Respiratory disorders associated with dystonia
Background: Respiratory difficulties are sometimes reported by patients with cranial‐cervical and other forms of dystonia, but the nature or mechanisms of the breathing problems have not been well characterized.Case Report: We review 13 dystonic patients with various respiratory complaints and describe their symptoms and response to treatment, including botulinum toxin (BoNT) injections.Discussion: Gasping, stridor, interrupted flow of speech, paradoxical breathing, dyspnea on exertion, and other respiratory symptoms reported by patients suggest involvement of the upper airways, chest, and diaphragm. BoNT injections may be, at least partially, beneficial in some patients.Conclusion: This series of patients draws attention to respiratory distress as a potentially serious, even life‐threatening, complication of dystonia. © 2012 Movement Disorder Society
- 3 December 2012
- Published by Wiley in Movement Disorders
- Vol. 27 (14) , 1816-1819
Respiratory disorders associated with dystonia
Background: Respiratory difficulties are sometimes reported by patients with cranial‐cervical and other forms of dystonia, but the nature or mechanisms of the breathing problems have not been well characterized.Case Report: We review 13 dystonic patients with various respiratory complaints and describe their symptoms and response to treatment, including botulinum toxin (BoNT) injections.Discussion: Gasping, stridor, interrupted flow of speech, paradoxical breathing, dyspnea on exertion, and other respiratory symptoms reported by patients suggest involvement of the upper airways, chest, and diaphragm. BoNT injections may be, at least partially, beneficial in some patients.Conclusion: This series of patients draws attention to respiratory distress as a potentially serious, even life‐threatening, complication of dystonia. © 2012 Movement Disorder Society
- Open Access
- 29 September 2012
- Published by Springer Nature in Neurology and Therapy
- Vol. 1 (1) , 1-8
Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease
Introduction Tetrabenazine (TBZ) reduces chorea related to Huntington disease (HD); however, it is uncertain whether this effect improves functionally relevant motor skills such as hand coordination and balance. The objective of this study was to provide pilot data regarding three motor function tests, which might be useful in monitoring symptom progression and therapeutic response, pending formal validation. Methods The authors assessed 11 ambulatory patients with HD-related chorea on two occasions: (1) while off TBZ (either prior to starting therapy or following a >24 h washout) and (2) when on a stable dose of TBZ, titrated to optimal effect. Study evaluations included the Jebsen-Taylor Hand Function Test (JTHFT) and Berg Balance Scale, a timed 25-foot walk, the Montreal Cognitive Assessment (MoCA) and the complete United Huntington Disease Rating Scale (UHDRS). Results Maximal chorea scores (UHDRS item 12) improved from 11.1 ± 2.9 to 8.5 ± 3.9 while on TBZ (P = 0.03), but we could not detect an improvement in functional measures while on TBZ in this small cohort. Scores of the JTHFT were globally slower than published normative data and correlated with MoCA summary scores, but not UHDRS chorea scores. Conclusions This pilot study did not detect significant functional gains with chorea suppression. The fact that performance on tests of hand function correlates with MoCA but not UHDRS chorea scores highlights the need for additional treatments targeted toward the cognitive aspects of HD.
- 29 September 2012
- Published by Springer Nature in Neurology and Therapy
- Vol. 1 (1) , 1-8
Open AccessEffect of Tetrabenazine on Motor Function in Patients with Huntington Disease
Introduction Tetrabenazine (TBZ) reduces chorea related to Huntington disease (HD); however, it is uncertain whether this effect improves functionally relevant motor skills such as hand coordination and balance. The objective of this study was to provide pilot data regarding three motor function tests, which might be useful in monitoring symptom progression and therapeutic response, pending formal validation. Methods The authors assessed 11 ambulatory patients with HD-related chorea on two occasions: (1) while off TBZ (either prior to starting therapy or following a >24 h washout) and (2) when on a stable dose of TBZ, titrated to optimal effect. Study evaluations included the Jebsen-Taylor Hand Function Test (JTHFT) and Berg Balance Scale, a timed 25-foot walk, the Montreal Cognitive Assessment (MoCA) and the complete United Huntington Disease Rating Scale (UHDRS). Results Maximal chorea scores (UHDRS item 12) improved from 11.1 ± 2.9 to 8.5 ± 3.9 while on TBZ (P = 0.03), but we could not detect an improvement in functional measures while on TBZ in this small cohort. Scores of the JTHFT were globally slower than published normative data and correlated with MoCA summary scores, but not UHDRS chorea scores. Conclusions This pilot study did not detect significant functional gains with chorea suppression. The fact that performance on tests of hand function correlates with MoCA but not UHDRS chorea scores highlights the need for additional treatments targeted toward the cognitive aspects of HD.
- 3 May 2012
- Published by Wiley in Movement Disorders
- Vol. 27 (8) , 935-946
Movement disorders in autoimmune diseases
Movement disorders have been known to be associated with a variety of autoimmune diseases, including Sydenham's chorea, pediatric autoimmune neuropsychiatric disorders associated with streptococcus, systemic lupus erythematosus, antiphospholipid syndrome, gluten sensitivity, paraneoplastic and autoimmune encephalopathies. Tremors, dystonia, chorea, ballism, myoclonus, parkinsonism, and ataxia may be the initial and even the only presentation of these autoimmune diseases. Although antibodies directed against various cellular components of the central nervous system have been implicated, the pathogenic mechanisms of these autoimmune movement disorders have not yet been fully elucidated. Clinical recognition of these autoimmune movement disorders is critically important as many improve with immunotherapy or dietary modifications, particularly when diagnosed early. We discuss here the clinical features, pathogenic mechanisms, and treatments of movement disorders associated with autoimmune diseases, based on our own experience and on a systematic review of the literature. © 2012 Movement Disorder Society
- 3 May 2012
- Published by Wiley in Movement Disorders
- Vol. 27 (8) , 935-946
Movement disorders in autoimmune diseases
Movement disorders have been known to be associated with a variety of autoimmune diseases, including Sydenham's chorea, pediatric autoimmune neuropsychiatric disorders associated with streptococcus, systemic lupus erythematosus, antiphospholipid syndrome, gluten sensitivity, paraneoplastic and autoimmune encephalopathies. Tremors, dystonia, chorea, ballism, myoclonus, parkinsonism, and ataxia may be the initial and even the only presentation of these autoimmune diseases. Although antibodies directed against various cellular components of the central nervous system have been implicated, the pathogenic mechanisms of these autoimmune movement disorders have not yet been fully elucidated. Clinical recognition of these autoimmune movement disorders is critically important as many improve with immunotherapy or dietary modifications, particularly when diagnosed early. We discuss here the clinical features, pathogenic mechanisms, and treatments of movement disorders associated with autoimmune diseases, based on our own experience and on a systematic review of the literature. © 2012 Movement Disorder Society